Sage Therapeutics (SAGE) Rating Reiterated by Cowen
Sage Therapeutics (NASDAQ:SAGE)‘s stock had its “buy” rating restated by investment analysts at Cowen in a research note issued on Monday.
Several other research firms have also recently weighed in on SAGE. Stifel Nicolaus restated a “buy” rating and set a $198.00 price target on shares of Sage Therapeutics in a report on Friday. BMO Capital Markets restated an “outperform” rating and set a $203.00 price target on shares of Sage Therapeutics in a report on Thursday. Needham & Company LLC boosted their price target on Sage Therapeutics from $100.00 to $193.00 and gave the stock a “buy” rating in a report on Thursday. Canaccord Genuity set a $191.00 price target on Sage Therapeutics and gave the stock a “buy” rating in a report on Thursday. Finally, Raymond James Financial restated a “buy” rating and set a $206.00 price target on shares of Sage Therapeutics in a report on Thursday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Sage Therapeutics has an average rating of “Buy” and an average price target of $171.21.
Sage Therapeutics (NASDAQ:SAGE) traded up $11.07 during trading hours on Monday, hitting $167.34. The stock had a trading volume of 4,670,600 shares, compared to its average volume of 599,461. Sage Therapeutics has a 52 week low of $44.55 and a 52 week high of $173.36.
Several institutional investors have recently bought and sold shares of SAGE. Bank of New York Mellon Corp lifted its stake in shares of Sage Therapeutics by 36.5% in the third quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock worth $168,834,000 after acquiring an additional 724,494 shares during the period. BlackRock Inc. lifted its stake in Sage Therapeutics by 5.9% in the second quarter. BlackRock Inc. now owns 3,031,548 shares of the biopharmaceutical company’s stock valued at $241,431,000 after buying an additional 168,424 shares during the period. New York State Common Retirement Fund lifted its stake in Sage Therapeutics by 258.0% in the third quarter. New York State Common Retirement Fund now owns 149,564 shares of the biopharmaceutical company’s stock valued at $9,318,000 after buying an additional 107,782 shares during the period. Farallon Capital Management LLC acquired a new position in Sage Therapeutics in the second quarter valued at approximately $7,964,000. Finally, State Street Corp lifted its stake in Sage Therapeutics by 7.7% in the second quarter. State Street Corp now owns 1,212,384 shares of the biopharmaceutical company’s stock valued at $96,558,000 after buying an additional 87,097 shares during the period. 95.40% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Sage Therapeutics (SAGE) Rating Reiterated by Cowen” was reported by Watch List News and is the property of of Watch List News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/sage-therapeutics-sage-rating-reiterated-by-cowen/1758021.html.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.